{"entity":{"id":"tempest-therapeutics","kind":"company","name":"Tempest Therapeutics","aka":["Tempest Therapeutics, Inc."],"tldr":"Tempest Therapeutics is a California company developing CAR-T cell treatments, immune cells engineered to find cancer, that target two markers at once. One is made inside the body; the other, made from a patient's own cells, is being tested in multiple myeloma.","summary":"Tempest Therapeutics, Inc., of Brisbane, California, describes in its August 2026 registration statement a pipeline of chimeric antigen receptor T cell candidates. Its lead programme, TPST-4003, is a dual CD19 and BCMA in vivo CAR-T candidate for immunology and oncology. In February 2026 it acquired rights to a dual-targeting CAR-T platform including TPST-2003, an autologous CD19 and BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma and POEMS syndrome.","asOf":"2026-11-04","links":[{"label":"SEC: Tempest Therapeutics Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm"},{"label":"Official website","url":"https://www.tempesttx.com/"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t","in-vivo-car-t"],"targets":["cd19","bcma"],"drugs":["tpst-4003","tpst-2003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 4 November 2026 in the S-1 filed with the SEC on 21 August 2026, a resale registration that incorporates the annual report by reference. The filing does not give phases or trial numbers for either candidate."],"hq":"Brisbane, CA","country":"US","companyType":"biotech","website":"https://www.tempesttx.com/","ticker":"TPST","stage":"public","investors":[],"funding":[]},"route":"/companies/tempest-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"tpst-2003","kind":"drug","name":"TPST-2003","route":"/drugs/tpst-2003/"},{"id":"tpst-4003","kind":"drug","name":"TPST-4003","route":"/drugs/tpst-4003/"}]}}